| Compound |
Molecular Targets |
Preclinical Use |
ClinicalTrials |
| ABT-737 |
Bcl-2 and Bcl-Xl(lownM affinity) |
Multiple myeloma;
Acutemyeloid leukemia;
Small celllung cancer;
Lymphoma |
Phase I/II |
| Navitoclax
(ABT-263) |
Bcl-Xl, Bcl-2, Bcl-w,Bcl-B |
Multiple myeloma;
Small celllung cancer;
Non-HodgkinLymphoma;
Chroniclymphocytic leukemia |
Phase I/IIa |
| Venetoclax
(ABT-199) |
Bcl-Xl, Bcl-2, Bcl-w,Bcl-B |
Multiple myeloma;
Small celllung cancer;
Chroniclymphocytic leukemia |
Phase I/II |
| Obatoclax(GX015-070) |
Bcl-2, Bcl-Xl, Bcl-w,Mcl-1 |
Myeloma;
Mantle celllymphoma |
Phase I/II |
| Gossypol (BL -193, AT-101) |
Mcl-1, Bcl-2, Bcl-Xl |
Head and neck tumors;
Malignant gliomas |
Phase II/III |
| Apogossypolone(ApoG2) |
Bcl-2, Mcl-1, Bcl-Xl(highest to lowestaffinity) |
Non-Hodgkins Lymphoma,Lymphoma |
Preclinical |
| TW-37 |
Bcl-w, Bcl-Xl, A1,Mcl-1, Bcl-2 |
Non-Hodgkins Lymphoma,Pancreatic, Lung |
Preclinical |
| Tetrocarcin A |
Bcl-2 and Bcl-Xl |
Leukemia and others |
Preclinical |
